Boehringer Ingelheim Names Brian Hilberdink as President, U.S. Human Pharma to Drive Growth and Impact
Ridgefield, CT, February 20, 2025 (PRNewswire) -- Boehringer Ingelheim Pharmaceuticals, Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma, a pivotal role as the company prepares for the launch of several new assets while expanding its existing portfolio. With over 25 years of experience in the pharmaceutical industry, Hilberdink has led multiple product launches, including blockbuster and rare disease biologics, and has held senior roles at LEO Pharma and Novo Nordisk. In his new position, Hilberdink will focus on fostering Boehringer’s culture and driving meaningful impact for patients.
Read full article here.